Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer
Launched by RIGSHOSPITALET, DENMARK · Dec 21, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how cancer treatments for early breast cancer may affect women's bone health and metabolism. Specifically, it aims to understand why some women experience changes in their bone density, blood sugar levels, and cholesterol after treatment. The researchers hope to find out more about these changes and identify potential warning signs that could help prevent serious health issues like diabetes or heart disease in breast cancer survivors.
To participate in this study, women who are postmenopausal and have early-stage breast cancer (stages I-III) may be eligible. The trial will involve 120 participants aged 50 to 70 years. For five years, they will have regular check-ups to measure their bone health, body composition, and metabolic health. Participants will also fill out questionnaires about their diet, physical activity, and quality of life. This important research could help doctors provide better care and prevention strategies for women recovering from breast cancer.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Postmenopausal
- • Breast cancer stage I-III
- • Eligible to receive (neo-)adjuvant chemotherapy/other antineoplastic treatment
- Exclusion Criteria:
- • Prior malignancy
- • Metabolic disease (diabetes mellitus etc)
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, Copenhagen ø, Denmark
Copenhagen, Danmark, Denmark
Patients applied
Trial Officials
Peter Schwarz, Prof, MD
Principal Investigator
Rigshospitalet, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials